Identifying the Effective Factors in the Death of Patients Receiving Convalescent Plasma

Leyli Yekefallah, P. Namdar, Saeedeh Mouri, S. Mohammadi
{"title":"Identifying the Effective Factors in the Death of Patients Receiving Convalescent Plasma","authors":"Leyli Yekefallah, P. Namdar, Saeedeh Mouri, S. Mohammadi","doi":"10.32598/jid.25.4.7","DOIUrl":null,"url":null,"abstract":"Background: Despite the fast spread of COVID-19 around the world, no definitive treatment has been found for the disease yet. Various drugs have been tried to reduce the mortality rate of the disease. In this regard, convalescent plasma therapy is a beneficial method to control the illness. Objective: This study aims to determine the outcomes of patients receiving this therapy in Bu-Ali Hospital, Qazvin, Iran. Methods: The present study is a case series of 60 samples. The samples were selected by purposive sampling method. The study was conducted after ethical approval and patients’ consent in 2020. The inclusion criteria were having a lung scan confirming the disease by an internist or infectious disease specialist, a positive PCR test, and a history of receiving plasma during treatment. Results: Out of 60 patients with COVID-19 who received convalescent plasma, 33 (55%) survived. The findings indicate that patients who received plasma and died were not significantly different from surviving patients regarding age, sex, underlying disease, and length of hospital stay (P>0.05). However, there was a significant difference between the deceased and surviving patients regarding plasma receiving time (P=0.005). Conclusion: If the convalescent plasma therapy of patients starts closer to the time of admission, the effect of therapy on reducing patient mortality will be greater.","PeriodicalId":91544,"journal":{"name":"Journal of inflammatory bowel diseases & disorders","volume":"88 3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of inflammatory bowel diseases & disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/jid.25.4.7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite the fast spread of COVID-19 around the world, no definitive treatment has been found for the disease yet. Various drugs have been tried to reduce the mortality rate of the disease. In this regard, convalescent plasma therapy is a beneficial method to control the illness. Objective: This study aims to determine the outcomes of patients receiving this therapy in Bu-Ali Hospital, Qazvin, Iran. Methods: The present study is a case series of 60 samples. The samples were selected by purposive sampling method. The study was conducted after ethical approval and patients’ consent in 2020. The inclusion criteria were having a lung scan confirming the disease by an internist or infectious disease specialist, a positive PCR test, and a history of receiving plasma during treatment. Results: Out of 60 patients with COVID-19 who received convalescent plasma, 33 (55%) survived. The findings indicate that patients who received plasma and died were not significantly different from surviving patients regarding age, sex, underlying disease, and length of hospital stay (P>0.05). However, there was a significant difference between the deceased and surviving patients regarding plasma receiving time (P=0.005). Conclusion: If the convalescent plasma therapy of patients starts closer to the time of admission, the effect of therapy on reducing patient mortality will be greater.
康复期血浆患者死亡的影响因素分析
背景:尽管COVID-19在全球迅速传播,但尚未找到针对该疾病的明确治疗方法。已经尝试了各种药物来降低这种疾病的死亡率。在这方面,恢复期血浆治疗是控制病情的有益方法。目的:本研究旨在确定伊朗Qazvin Bu-Ali医院接受这种治疗的患者的预后。方法:本研究是一个60个样本的病例系列研究。采用目的抽样法选取样本。该研究是在2020年获得伦理批准和患者同意后进行的。纳入标准是由内科医生或传染病专家进行肺部扫描确认疾病,PCR检测阳性,以及治疗期间接受血浆治疗的历史。结果:60例接受恢复期血浆治疗的新冠肺炎患者中,33例(55%)存活。结果显示,接受血浆治疗后死亡的患者在年龄、性别、基础疾病、住院时间等方面与存活患者无显著差异(P>0.05)。然而,在接受血浆治疗的时间上,死亡患者与存活患者有显著差异(P=0.005)。结论:如果患者的恢复期血浆治疗在入院前开始,治疗对降低患者死亡率的效果将更大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信